Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

Journal of Clinical Pharmacology

Volumn 48, Issue 4, 2008, Pages 475-484

  Small, David S ^a   Farid, Nagy A ^a   Payne, Christopher D ^a   Weerakkody, Govinda J ^a   Li, Ying G ^a   Brandt, John T ^a   Salazar, Daniel E ^b   Winters, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Clopidogrel; Drug interaction; Lansoprazole; Prasugrel

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; CLOPIDOGREL; DRUG METABOLITE; LANSOPRAZOLE; PRASUGREL; R 106583; R 119251; R 138727; R 95913; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; EPISTAXIS; FEMALE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; MAXIMUM ALLOWABLE CONCENTRATION; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN BRUISING; STOMACH PH; THROMBOCYTE AGGREGATION INHIBITION; TURBIDIMETRY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; THIOPHENES; TICLOPIDINE;

EID: 40749094082     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008315310     Document Type: Article

References (21)

1. Fuster V., Moreno PR, Fayad ZA, Corti R., Badimon JJ Atherothrombosis and high-risk plaque: part I. Evolving concepts. J Am Coll Cardiol. 2005 ; 46: 937-954.
2. Ruggeri ZM Platelets in atherothrombosis. Nat Med. 2002 ; 8: 1227-1234.
3. Gachet C. Regulation of platelet functions by p2 receptors. Annu Rev Pharmacol Toxicol. 2006 ; 46: 277-300.
4. Clopidogrel [package insert]. Bridgewater, NJ: Bristol-Myers Squibb / Sanofi Pharmaceuticals Partnership ; 2007.
5. Caplain H., Donat F., Gaud C., Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999 ; 25: 29-33.
6. Lins R., Broekhuysen J., Necciari J., Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost. 1999 ; 25: 29-33.
7. Farid NA, Payne CD, Small D., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 ; 8: 735-741.
8. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet Inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 ; 152: 627-635.
9. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007 ; 35: 1096-1104.
10. Rehmel JLF, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent with the cytochromes P450. Drug Metab Dispos. 2006 ; 34: 600-607.
11. Niitsu Y., Jakubowski JA, Sugidachi A., Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005 ; 31: 184-194.
12. Sugidachi A., Ogawa T., Hasegawa M., et al. Active metabolites of CS-747 (Prasugrel, LY640315) and clopidogrel show similar in vitro P2Y12 receptor blockade but greater in vivo potency of CS-747 [abstract]. J Thromb Haemost. 2005 ; 3 (suppl 1). P1109.
13. Sugidachi A., Asai F., Ogawa T., et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000 ; 129: 1439-1446.
14. Brandt JT, Payne CD, Weerakkody GJ, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 ; 153 :e9-66.e16.
15. Ogawa T., Sugidachi A., Isobe T., et al. Greater in vivo potency of prasugrel (CS-747, LY640315) vs. clopidogrel is not explained by differential activity of active metabolites [abstract P2954]. Presented at: Program and Abstracts of the European Society of Cardiology ; September 3-7, 2005 ; Stockholm, Sweden.
16. Small DS, Payne CD, Ferguson-Sells LR, et al. Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response [abstract 510]. Am J Cardiol. 2006 ; 98 (suppl 1). 200.
17. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1994 ; 48: 404-430.
18. Farid NA, McIntosh M., Garofolo F., et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007 ; 21: 1-12.
19. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies: Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Available at: http://www.fdagov/cder/guidance/2635fnl.htm. Accessed May 11, 2007.
20. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther. 2007 ; 12: 205-212.
21. Jernberg T., Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006 ; 27: 1166-1173.